Debbie Stephens – University of Utah
Chitra Hosing – MD Anderson Cancer Center
Susan O’Brien – University of California Irvine Medical Center
Nitin Jain – MD Anderson Cancer Center
Alessandra Ferrajoli – MD Anderson Cancer Center, Houston, Texas
Danielle Brander – Duke University School of Medicine
Clare Sun – National Heart, Lung and Blood Institute
Sameer Parikh – Mayo Clinic
Dai Chihara – MD Anderson Cancer Centre
Sandeep Dave – Duke University School of Medicine
Sandeep Dave – Duke University School of Medicine
Christopher Flowers – MD Anderson Cancer Center
Sattva Neelapu – MD Anderson Cancer Center
Caron Jacobson – Dana Farber Cancer Institute
Paolo Strati – MD Anderson Center
John Leonard – Weill Cornell Medicine
Elizabeth Brem – UCI Health Cancer Center
Julie Vose – University of Nebraska
Swami Iyer – MD Anderson Cancer Center
Ranjana Advani – Stanford University
Paolo Strati – MD Anderson Center
Swetha Kambhampati – City of Hope
It is our pleasure to invite you to participate in this one-of-a-kind event.
If you need additional information please contact us at:
MD Education Ltd
4/4a Bloomsbury Square,
London, WC1A 2RP
MD Education USA LLC
4600 140th Avenue North, Suite 180,
Clearwater, Florida 33762
MD Anderson Cancer Center, Houston, Texas
Profile: Nitin Jain, MD
Nitin Jain, M.D., is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MDACC followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MDACC in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Since 2021, he has also served as Director, Cellular Therapy Program within the Department of Leukemia, MDACC. Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others. He has won many awards during his career including Sardari Lal Kalra Gold Medal in Microbiology from AIIMS and Merit Award from the American Society of Clinical Oncology (ASCO). He secured first rank at the national level in India in the medical school (AIIMS) entrance examination. He received High-Impact Clinical Research Support Award from MD Anderson Cancer Center in the year 2014 and 2016. He has served as faculty on American Society of Hematology CRTI workshop from 2017-2019. He is recipient of Sabin Family Foundation Award in 2018. In 2020, he received MD Anderson Faculty Scholar award. In 2021, he was appointed Director of the CAR-T program for the Leukemia Department, MDACC. In 2022, he received LLS Career Development Award and LLS Translational Research Program Award.
Alessandro Vannucchi is a Professor of Hematology and head of Center, Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, University of Florence, Italy.
Director of the Denothe Excellence Center, University of Florence. Chair of the MPN board of GIMEMA, and Principal Investigator of MYNERVA research group, Italy.
Paolo Strati MD is currently an Assistant Professor, Term Tenure Track, in the Department of Lymphoma and Myeloma with a joint appointment in the Department of Translational Molecular Pathology, at the University of Texas MD Anderson Cancer Center, in Houston, TX, and previously served as Assistant Professor at the Mayo Clinic, in Rochester (MN).
Dr. Strati earned his medical degree cum laude from the San Raffaele University of Milan (Italy) in 2008, and completed an Internal Medicine Residency at the same institution and, subsequently, at the Mayo Clinic, in Rochester (MN). He also completed a Hematology-Oncology Fellowship at MD Anderson Cancer Center, a Leukemia and Lymphoma fellowship at the same institution, and a Malignant Hematology fellowship at the Barts Cancer Institute, in London (UK).
Dr. Strati is a recognized expert in the field of immunotherapy and cellular therapy for the treatment of B-cell lymphoma, and he is the principal investigator of multiple clinical trials and translational projects related to this topic. He is author of several peer-reviewed manuscripts published on high impact journal, including Blood and Lancet Haematology, and he is regularly invited to present his work at international scientific meetings, including the American Society of Hematology and the American Society of Clinical Oncology conference. In light of his research accomplishments, he has received multiple grants and awards, including a NIH R21 grant, the Lymphoma Research Foundation Career Development Award and the Leukemia Lymphoma Society Career Development Award.
Dr. Strati is committed to gain further insight into the biology of the lymphoma immune microenvironment, and to manipulate its components successfully, in order to develop novel effective therapies and to decrease the toxicity of treatment strategies already available for patients with B-cell lymphoma.
MD Anderson Cancer Center, Houston, Texas
Dr. Sattva S Neelapu is a tenured Professor and Deputy Chair in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston, Texas. He completed medical school in India, Internal Medicine residency in New York, and clinical fellowship in Medical Oncology and postdoctoral fellowship in tumor immunology and immunotherapy at the National Cancer Institute, Bethesda, Maryland. As a physician-scientist at MD Anderson, his research is focused on clinical and translational development of novel immunotherapies for B-cell malignancies. His work on the pivotal clinical trial of axicabtagene ciloleucel CD19 CAR T-cell therapy in aggressive B-cell lymphomas led to its FDA approval as the first CAR T-cell therapy for lymphoma. Dr. Neelapu has authored or co-authored over 250 publications. He is nationally and internationally recognized for his expertise in CAR T-cell therapy in lymphomas and management of toxicities associated with CAR T-cell therapy.
Dr. Elizabeth Brém is currently a Clinical Associate Professor at the University of California, Irvine, with a clinical focus in lymphomas, CLL, and multiple myeloma. She earned her medical degree from the University of Buffalo summa cum laude with thesis honors and completed her residency in Internal Medicine and fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA. Dr. Brém serves as the chair of the University of California Hematologic Malignancies Consortium Lymphoma/CLL committee and is an active member of ASH, having served on a number of committees and as a former Associate Editor of ASH Clinical News. Dr. Brém is also active in the NCTN and is currently the study chair of SWOG S1918, a study for patients age 75 and older with a new diagnosis of DLBCL. She has participated in a number of high-profile mentoring programs and in 2021 was awarded the Coltman Fellowship from the Hope Foundation to support her efforts on S1918.
